A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes.
Although imatinib may be effective in hypereosinophilic syndromes, the exact response kinetics are not known. Imatinib was administered at 100-400 mg/d each week in a 12-week response-oriented schedule, targeting a complete clinical and haematological remission (CR). CR was achieved in 11/23 patients (6/6 with FIP1L1-PDGRFA rearrangement and 5/17 without, P = 0.006), most after 2 weeks of 100 mg/d imatinib. The maximum imatinib dose had no effect in early unresponsive patients. Low-dose, short-course imatinib may represent a rational choice for identifying responsive cases, both within and outside the pre-defined FIP1L1 rearrangement subset.
Intermesoli
Tamara
T
Unità Strutturale Complessa di Ematologia, Ospedali Riuniti, Bergamo, Italy.
Delaini
Federica
F
Acerboni
Sara
S
Salmoiraghi
Silvia
S
Spinelli
Orietta
O
Guerini
Vittoria
V
Vannucchi
Alessandro M
AM
Mappa
Silvia
S
Rossi
Giuseppe
G
Rossi
Valentina
V
Di Bona
Eros
E
Paratore
Simona
S
Carobbio
Alessandra
A
Rambaldi
Alessandro
A
Barbui
Tiziano
T
Bassan
Renato
R
D000328:Adult; D000368:Aged; D001549:Benzamides; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004804:Eosinophils / Q000473:pathology; D005260:Female; D015321:Gene Rearrangement; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy* / Q000235:genetics; D000068877:Imatinib Mesylate; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D010879:Piperazines / Q000008:administration & dosage* / Q000627:therapeutic use; D011743:Pyrimidines / Q000008:administration & dosage* / Q000627:therapeutic use; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics; D016896:Treatment Outcome; D055815:Young Adult; D039221:mRNA Cleavage and Polyadenylation Factors / Q000235:genetics
D001549:Benzamides; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; C479819:FIP1L1-PDGFRA fusion protein, human; D020796:Receptor, Platelet-Derived Growth Factor alpha